复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

交易中 05-07 10:05:45

19.140

+0.230

+1.22%

最高19.280	最低18.950	成交量37.90万
今开18.950	昨收18.910	日振幅1.75%
总市值508.93亿	流通市值103.54亿	总股本26.59亿
成交额726.16万	换手率0.07%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":19.14,"timestamp":1778119489052,"preClose":18.91,"halted":0,"volume":379000,"delay":0,"changeRate":0.012162876784769985,"floatShares":540971500,"shares":2659000000,"eps":1.462242778369572,"marketStatus":"交易中","change":0.23,"latestTime":"05-07 10:05:45","open":18.95,"high":19.28,"low":18.95,"amount":7261625,"amplitude":0.017451,"askPrice":19.16,"askSize":6500,"bidPrice":19.12,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":1.5081387796541135,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1778126400000},"marketStatusCode":2,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":18.91,"dividendRate":0.018286,"openAndCloseTimeList":[[1778117400000,1778126400000],[1778130000000,1778140800000]],"volumeRatio":1.590602,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":24.79,"timestamp":1778119543000,"preClose":24.77,"halted":0,"volume":6880500,"delay":0,"premium":"-32.94"}},"requestUrl":"/m/hq/s/02196/tweets","defaultTab":"tweets","newsList":[{"id":"2633839831","title":"复星医药（600196）披露控股子公司药品获注册批准的公告，5月6日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633839831","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633839831?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:31","pubTimestamp":1778059872,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，复星医药报收于24.77元，较前一交易日下跌0.48%，最新总市值为661.47亿元。该股当日开盘24.83元，最高24.96元，最低24.68元，成交额达5.82亿元，换手率为1.11%。近日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司重庆药友制药有限责任公司获得国家药品监督管理局批准，硝普钠注射液获准上市。2025年中国境内销售额约为1.12亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","600196","BK1593","BK0060","BK0187","BK0096","BK0196","BK1191","BK0028","BK1515","BK0012","BK0175","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193005509","title":"复星医药4月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193005509","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193005509?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:36","pubTimestamp":1777538217,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年4月30日发布2026年4月股份变动月报表。公告显示，公司于报告期内未新增发行股份，亦无股份购回及注销，整体股本结构保持不变。截至2026年4月30日，公司法定注册股本总额为人民币2,670,429,325元。期权与激励方面，公司依然维持此前公布的2025年A股期权计划与2025年H股受限制股份单位计划。公告由卓佳证券登记有限公司提交。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685178","title":"复星医药(600196.SH)控股子公司硝普钠注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631685178?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:27","pubTimestamp":1777537648,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司重庆药友制药有限责任公司就硝普钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为(1)高血压急症，如高血压危象、高血压脑病、恶性高血压、嗜铬细胞瘤手术前后阵发性高血压等的紧急降压，也可用于外科麻醉期间进行控制性降压;(2)急性心力衰竭，包括急性肺水肿，亦用于急性心肌梗死或瓣膜(二尖瓣或主动脉瓣)关闭不全时的急性心力衰竭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","02196","BK0096","600196","BK1515","BK0060","BK0175","BK0187","BK0188","BK1593","BK0183","BK1191","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631545160","title":"复星医药2026年一季报：扣非净利同比增长21.96% 将持续深化数字化与AI战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2631545160","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631545160?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:55","pubTimestamp":1777474529,"startTime":"0","endTime":"0","summary":"中国网财经4月29日讯昨日，复星医药(600196.SH；02196.HK)公布的“2026年第一季度业绩报告”显示，公司实现营业收入100.73亿元，同比增长6.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293725107371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293725107371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1593","02196","BK0096","AGIX","BK0028","BK0187","BK0012","BK0196","BK0239","600196","AIPO","BK0183","CHAT","BK1191","BK1515","ARTY","BK0060","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331305","title":"图解复星医药一季报：第一季度单季净利润同比增长13.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331305","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630331305?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:04","pubTimestamp":1777374244,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药2026年一季报显示，一季度公司主营收入100.73亿元，同比上升6.93%；归母净利润8.71亿元，同比上升13.87%；扣非净利润5.01亿元，同比上升21.96%；负债率48.22%，投资收益6.18亿元，财务费用2.22亿元，毛利率49.7%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486439","title":"复星医药筹划出售资产；诺诚健华一季度净利润同比增长488.93%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486439","media":"每日经济新闻","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629486439?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985208,"startTime":"0","endTime":"0","summary":"｜2026年4月24日星期五｜NO.1九洲药业一季度净利润1.72亿元同比减少31.22%4月23日，九洲药业公告，公司2026年第一季度实现营业收入12.01亿元，同比下降19.43%；利润总额2.20亿元，同比下降29.20%；归属于上市公司股东的净利润1.72亿元，同比减少31.22%，主要系销售业务减少所致；经营活动产生的现金流量净额1.36亿元，同比下降52.41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716839096.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716839096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","159938","600196","02196","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629101662","title":"大摩：升复星医药(02196)收入预测 目标价32港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2629101662","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629101662?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:51","pubTimestamp":1776847909,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，将复星医药(02196)2026至2028年收入预测上调3%，基于创新药销售额上升，以及预期每年入账约8亿元人民币的经常性授权收入。该行予H股目标价32港元，评级“增持”。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600196","EWH","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756773","title":"每周股票复盘：复星医药（600196）股东质押6.9亿股用于还债","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756773","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756773?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:10","pubTimestamp":1776535818,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，复星医药报收于26.15元，较上周的26.48元下跌1.25%。本周关注点公司公告汇总：复星高科技质押69,000,000股A股股份，用于偿还债务。公司公告汇总复星医药关于股东部分股份质押的公告上海复星医药（集团）股份有限公司于2026年4月15日接到控股股东复星高科技通知，其已将所持公司69,000,000股A股股份质押给中国银行股份有限公司上海市黄浦支行，质押起始日为2026年4月14日，到期日为2026年7月16日，融资用途为偿还债务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0096","BK0175","BK0187","BK0188","BK0012","BK0196","BK0028","BK1191","BK1593","BK0060","600196","02196","BK0239","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627295299","title":"复星医药（600196）披露股东部分股份质押公告，4月16日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627295299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627295299?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:20","pubTimestamp":1776331258,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，复星医药报收于26.7元，较前一交易日下跌0.37%，最新总市值为713亿元。近日，复星医药发布《关于股东部分股份质押的公告》。本次质押后，复星高科技累计质押公司股份数量为545,275,000股，约占公司总股本的20.42%。复星高科技及其一致行动人合计持有公司36.24%股份，累计质押股份占其所持股份的56.34%。上述质押股份不存在用于业绩补偿或其他保障用途的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600031350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0196","BK1191","BK0188","BK0060","600196","BK0012","02196","BK0187","BK0239","BK1515","BK0175","BK0096","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627040795","title":"复星医药：控股股东质押6900万股 占总股本的2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627040795","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627040795?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:11","pubTimestamp":1776244260,"startTime":"0","endTime":"0","summary":"4月15日，复星医药（600196/02196）发布公告，控股股东复星高科技将其持有的6900万股股份办理质押，占其所持股份的7.18%及公司总股本的2.58%；截至2026年4月14日，复星高科技及其一致行动人累计质押股份5.45亿股，占其所持股份的56.34%及公司总股本的20.42%。2025年，复星医药实现收入416.62亿元，归母净利润33.71亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705999693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0196","BK0028","BK0175","BK0183","BK1593","600196","BK0188","02196","BK0096","BK0187","BK1191","BK1515","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","LU1093756168.USD","REGN","02196","BK4588","NVOX","002437","301087","LU0154236417.USD","IE00BKVL7J92.USD","BK4585","603087","LU1093756325.SGD","600196","300558","IE00BZ1G4Q59.USD","688177","600513","NVO","BK4599","NVOH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419777","title":"复星医药(600196.SH)：HLX05-N(即重组抗EGFR人鼠嵌合单克隆抗体注射液)开展Ⅰ期临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419777?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:05","pubTimestamp":1776157559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX05-N用于转移性结直肠癌治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后就该药品开展相关临床研究。HLX05-N系集团自主研发的西妥昔单抗注射液生物类似药，拟用于转移性结直肠癌及头颈部鳞状细胞癌治疗。根据IQVIA MIDASTM最新数据，2025年，西妥昔单抗注射液于全球范围的销售额约为16.58亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","BK0028","BK0175","BK0183","BK1593","600196","BK0188","02196","BK0096","BK0187","BK1191","BK1515","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419136","title":"复星医药：控股子公司FKC289注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419136","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419136?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:56","pubTimestamp":1776156976,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月14日，复星医药(600196.SH)公告称，公司控股子公司复星凯瑞收到国家药监局关于同意FKC289注射液开展I/II期临床试验的批准。该药品为靶向BCMA和CD19的基因修饰CAR-T细胞产品，拟用于复发/难治原发性轻链淀粉样变及复发/难治膜性肾病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704439910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704439910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0060","BK0096","BK0196","BK0012","BK0175","BK0183","02196","BK0188","BK1191","BK0028","BK1515","BK1593","600196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627107719","title":"港股公告掘金 | 胜宏科技今日起招股，引入CPE Rosewood、Janchor Fund等基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2627107719","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627107719?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:22","pubTimestamp":1776043379,"startTime":"0","endTime":"0","summary":"【重大事项】胜宏科技(02476)拟全球发售8334.8万股H股，引入CPE Rosewood、Janchor Fund等基石投资者复星医药(02196)：氟比洛芬酯注射液获注册批准复宏汉霖(02696)：帕妥珠曲妥珠单抗注射液(皮下注射)生物类似药HLX319 的1期临床研究于中国境内完成首例受试者给药高视医疗(02407)：高视创新获得角膜共聚焦显微镜CE注册证书荣昌生物(09995)：维迪西","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01519","BK0197","09857","06960","BK4588","BK0214","LU0469268626.HKD","BK1593","300476","02476","BK1191","BK1128","BK1515","LU1808992512.USD","LU1979443071.USD","CPE","02196","SGXZ49509284.SGD","IPOS","VXUS","BK4213","SGXZ81163826.USD","BK1116","LU1934453819.USD","LU0256331488.USD","BK1151"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626748195","title":"复星医药(02196)：氟比洛芬酯注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626748195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626748195?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:40","pubTimestamp":1775814021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，近日，公司控股子公司重庆药友制药有限责任公司就氟比洛芬酯注射液的药品注册申请获国家药品监督管理局批准，本次获批适应症为用于术后及癌症的镇痛。该药品为集团自主研发的化学药品。截至2026年3月，集团现阶段针对该药品的累计研发投入约为人民币0.34亿元(未经审计)。根据IQVIA CHPA最新数据，2025年，氟比洛芬酯注射液于中国境内(不包括港澳台地区)的销售额约为人民币11.58亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0028","BK0188","BK0012","600196","02196","BK0196","BK0183","BK0096","BK0239","BK1593","BK1191","BK0060","BK1515","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130162660","title":"复星医药子公司氟比洛芬酯注射液药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1130162660","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130162660?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:39","pubTimestamp":1775813955,"startTime":"0","endTime":"0","summary":"复星医药宣布，其子公司提交的氟比洛芬酯注射液药品注册申请已获得国家药品监督管理局（NMPA）正式批准。\n此次获批标志着该药物在中国市场的商业化进程取得重要进展，有望为患者提供新的治疗选择。氟比洛芬酯注射液作为一种非甾体抗炎药，主要用于术后镇痛及炎症控制。\n公司表示将积极推进后续生产及市场推广工作，严格遵循监管要求，确保药品质量与用药安全。这一进展也体现了复星医药在创新药研发领域的持续投入与成果转化能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK0096","BK0175","BK0187","BK0188","BK0012","BK0196","BK0028","BK1191","BK1593","BK0060","600196","02196","BK0239","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626518842","title":"复星医药最新公告：控股子公司获药品补充申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626518842","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626518842?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:29","pubTimestamp":1775726995,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0196","BK0012","600196","BK1191","BK1593","BK1515","BK0175","02196","BK0028","BK0096","BK0187","BK0239","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625793286","title":"复星医药年营收417亿：境内收入同比降4% 陈战宇卸任CFO职务","url":"https://stock-news.laohu8.com/highlight/detail?id=2625793286","media":"雷递网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625793286?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:49","pubTimestamp":1775476195,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司（公司代码：600196 公司简称：复星医药）日前发布截至2025年12月31日的财报。财报显示，复星医药2025年营收为416.62亿元，较上年同期的410.67亿元增长1.45%。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110177877379919843687.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110177877379919843687.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33209/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["600196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506716","title":"复星医药：董事会审议通过《关于聘任高级管理人员的议案》","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506716","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624506716?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:59","pubTimestamp":1775131140,"startTime":"0","endTime":"0","summary":"证券日报网讯4月2日，复星医药发布公告称，公司第十届董事会第二十七次会议（临时会议）审议通过《关于聘任高级管理人员的议案》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693660329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","600196","BK0028","BK0188","BK0196","BK0096","BK0183","BK1515","BK0239","BK0012","BK1593","02196","BK0060","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193076765","title":"复星医药2026年3月股份变动月报表，无新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1193076765","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193076765?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120561,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年4月2日披露2026年3月股份变动月报表。公告显示，报告期内公司未发生新增发行、回购或注销股份，各类股本数量与上月保持一致。根据公告，截至2026年3月底，公司H股注册股本为551,940,500股，当月无增减变动；A股注册股本为2,118,488,825股，亦无增减变动。在期权及激励计划方面，公告披露的2025年A股期权计划和2025年H股受限制股份单位计划本期内无期权行使或因行使导致的新股发行，也无库藏股转让。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9589a36a1b64e7c7d7a94166c3b09e9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0342},{"period":"1month","weight":-0.0909},{"period":"3month","weight":-0.0785},{"period":"6month","weight":-0.1566},{"period":"1year","weight":0.383},{"period":"ytd","weight":-0.0327}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026005},{"month":5,"riseRate":0.428571,"avgChangeRate":0.031999},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}